Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Venous Thromboembolism | 21 | 2024 | 1882 | 3.930 |
Why?
|
Antithrombin III Deficiency | 4 | 2024 | 28 | 2.740 |
Why?
|
Antithrombin III | 6 | 2024 | 128 | 2.560 |
Why?
|
Thrombophilia | 5 | 2024 | 308 | 2.380 |
Why?
|
Hemophilia A | 6 | 2022 | 357 | 2.170 |
Why?
|
Anticoagulants | 19 | 2024 | 4862 | 1.770 |
Why?
|
Hemostasis | 4 | 2023 | 467 | 1.480 |
Why?
|
Heparin | 4 | 2021 | 1630 | 1.450 |
Why?
|
Hemostatics | 3 | 2022 | 247 | 1.400 |
Why?
|
Frameshift Mutation | 2 | 2024 | 393 | 1.390 |
Why?
|
Upper Extremity Deep Vein Thrombosis | 2 | 2021 | 25 | 1.380 |
Why?
|
Fibrinogens, Abnormal | 2 | 2020 | 10 | 1.380 |
Why?
|
Afibrinogenemia | 2 | 2020 | 17 | 1.370 |
Why?
|
Postthrombotic Syndrome | 3 | 2014 | 30 | 1.300 |
Why?
|
Anemia, Sickle Cell | 5 | 2022 | 1067 | 1.280 |
Why?
|
Drug Monitoring | 4 | 2021 | 962 | 1.230 |
Why?
|
Venous Thrombosis | 8 | 2020 | 1327 | 1.200 |
Why?
|
Blood Coagulation Disorders | 2 | 2023 | 349 | 1.170 |
Why?
|
Hemorrhage | 8 | 2021 | 3461 | 0.950 |
Why?
|
Heterozygote | 2 | 2024 | 2794 | 0.950 |
Why?
|
Thrombolytic Therapy | 4 | 2021 | 2059 | 0.860 |
Why?
|
Hemophilia B | 2 | 2016 | 83 | 0.840 |
Why?
|
Deamino Arginine Vasopressin | 1 | 2022 | 87 | 0.800 |
Why?
|
Thrombosis | 4 | 2023 | 2949 | 0.770 |
Why?
|
Blood Coagulation | 5 | 2022 | 1166 | 0.750 |
Why?
|
22q11 Deletion Syndrome | 1 | 2021 | 18 | 0.730 |
Why?
|
Partial Thromboplastin Time | 2 | 2019 | 202 | 0.690 |
Why?
|
Thoracic Outlet Syndrome | 1 | 2021 | 97 | 0.670 |
Why?
|
Databases, Factual | 4 | 2024 | 8067 | 0.670 |
Why?
|
Catheterization, Swan-Ganz | 1 | 2019 | 87 | 0.640 |
Why?
|
Adolescent | 37 | 2024 | 88835 | 0.640 |
Why?
|
Cytapheresis | 1 | 2018 | 8 | 0.640 |
Why?
|
Child | 36 | 2024 | 80564 | 0.590 |
Why?
|
Klinefelter Syndrome | 1 | 2018 | 48 | 0.590 |
Why?
|
Child, Preschool | 24 | 2024 | 42500 | 0.580 |
Why?
|
Vena Cava, Inferior | 2 | 2018 | 463 | 0.580 |
Why?
|
Pulmonary Embolism | 4 | 2021 | 2598 | 0.570 |
Why?
|
Exercise Therapy | 2 | 2022 | 937 | 0.570 |
Why?
|
Factor Xa | 2 | 2019 | 166 | 0.570 |
Why?
|
Mesenteric Arteries | 1 | 2018 | 177 | 0.570 |
Why?
|
Popliteal Artery | 1 | 2019 | 301 | 0.560 |
Why?
|
Nomograms | 1 | 2019 | 235 | 0.550 |
Why?
|
Fibrinogen | 1 | 2020 | 895 | 0.550 |
Why?
|
Thrombocytopenia | 2 | 2016 | 1171 | 0.540 |
Why?
|
von Willebrand Disease, Type 3 | 2 | 2013 | 6 | 0.530 |
Why?
|
von Willebrand Disease, Type 2 | 1 | 2016 | 8 | 0.530 |
Why?
|
Valproic Acid | 1 | 2019 | 445 | 0.520 |
Why?
|
Arterial Occlusive Diseases | 1 | 2019 | 729 | 0.490 |
Why?
|
Infant | 21 | 2024 | 36386 | 0.490 |
Why?
|
Angioplasty, Balloon | 1 | 2018 | 608 | 0.470 |
Why?
|
Antithrombin Proteins | 1 | 2014 | 10 | 0.460 |
Why?
|
Decision Support Systems, Clinical | 1 | 2024 | 1175 | 0.460 |
Why?
|
Thromboembolism | 1 | 2021 | 1003 | 0.450 |
Why?
|
Lower Extremity | 2 | 2019 | 1226 | 0.450 |
Why?
|
Fibrinolytic Agents | 2 | 2023 | 2080 | 0.450 |
Why?
|
Point Mutation | 1 | 2019 | 1590 | 0.440 |
Why?
|
Decompression, Surgical | 1 | 2018 | 603 | 0.430 |
Why?
|
Blood Coagulation Factors | 1 | 2016 | 371 | 0.430 |
Why?
|
Central Nervous System Neoplasms | 1 | 2020 | 916 | 0.400 |
Why?
|
von Willebrand Diseases | 1 | 2013 | 135 | 0.390 |
Why?
|
Orthopedic Procedures | 1 | 2021 | 1280 | 0.380 |
Why?
|
Dermatofibrosarcoma | 1 | 2011 | 50 | 0.370 |
Why?
|
Sinus Thrombosis, Intracranial | 1 | 2012 | 109 | 0.370 |
Why?
|
Factor VIII | 4 | 2022 | 347 | 0.370 |
Why?
|
Young Adult | 18 | 2024 | 59889 | 0.360 |
Why?
|
Body Weight | 2 | 2021 | 4622 | 0.360 |
Why?
|
Sports | 2 | 2016 | 698 | 0.360 |
Why?
|
Ischemia | 1 | 2019 | 1909 | 0.360 |
Why?
|
Histiocytic Sarcoma | 1 | 2011 | 41 | 0.350 |
Why?
|
Infant, Newborn | 11 | 2022 | 26346 | 0.350 |
Why?
|
Humans | 65 | 2024 | 765968 | 0.350 |
Why?
|
Genes, p16 | 1 | 2011 | 157 | 0.350 |
Why?
|
Male | 41 | 2024 | 363698 | 0.350 |
Why?
|
Acute Chest Syndrome | 1 | 2010 | 32 | 0.340 |
Why?
|
Brain Ischemia | 1 | 2022 | 3000 | 0.320 |
Why?
|
Anticonvulsants | 1 | 2019 | 1921 | 0.320 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2011 | 230 | 0.310 |
Why?
|
Wilms Tumor | 1 | 2011 | 379 | 0.310 |
Why?
|
Prednisone | 2 | 2011 | 1565 | 0.310 |
Why?
|
Ribs | 2 | 2021 | 254 | 0.300 |
Why?
|
Aneurysm, False | 1 | 2011 | 264 | 0.300 |
Why?
|
Executive Function | 1 | 2017 | 1391 | 0.300 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 691 | 0.290 |
Why?
|
Stroke | 2 | 2022 | 9747 | 0.290 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2011 | 540 | 0.290 |
Why?
|
Female | 35 | 2024 | 396112 | 0.290 |
Why?
|
von Willebrand Factor | 3 | 2016 | 676 | 0.270 |
Why?
|
Lymphoma, Follicular | 1 | 2011 | 459 | 0.270 |
Why?
|
Genetic Association Studies | 1 | 2016 | 2741 | 0.270 |
Why?
|
Pelvis | 1 | 2011 | 738 | 0.260 |
Why?
|
Risk Factors | 16 | 2024 | 74840 | 0.260 |
Why?
|
Retrospective Studies | 16 | 2024 | 81514 | 0.250 |
Why?
|
Blood Coagulation Tests | 2 | 2017 | 263 | 0.250 |
Why?
|
Mutation | 5 | 2023 | 30198 | 0.240 |
Why?
|
Hospitalization | 2 | 2024 | 10808 | 0.240 |
Why?
|
Follow-Up Studies | 6 | 2024 | 39193 | 0.230 |
Why?
|
Drug Dosage Calculations | 2 | 2021 | 116 | 0.210 |
Why?
|
Quality of Life | 2 | 2016 | 13462 | 0.210 |
Why?
|
Adult | 19 | 2023 | 223044 | 0.210 |
Why?
|
Neoplasms, Second Primary | 1 | 2011 | 1050 | 0.210 |
Why?
|
Body Mass Index | 1 | 2021 | 13039 | 0.210 |
Why?
|
Cognition Disorders | 1 | 2017 | 3967 | 0.200 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2017 | 5753 | 0.190 |
Why?
|
Embolization, Therapeutic | 1 | 2011 | 1403 | 0.180 |
Why?
|
Glucocorticoids | 1 | 2010 | 2132 | 0.180 |
Why?
|
Prognosis | 4 | 2024 | 29922 | 0.170 |
Why?
|
Phenotype | 4 | 2023 | 16721 | 0.170 |
Why?
|
Severity of Illness Index | 3 | 2021 | 15880 | 0.170 |
Why?
|
Antithrombins | 1 | 2023 | 295 | 0.170 |
Why?
|
Acute Generalized Exanthematous Pustulosis | 1 | 2009 | 14 | 0.170 |
Why?
|
Amoxicillin-Potassium Clavulanate Combination | 1 | 2009 | 32 | 0.160 |
Why?
|
Exercise | 1 | 2016 | 5937 | 0.160 |
Why?
|
Half-Life | 2 | 2019 | 644 | 0.150 |
Why?
|
Obesity | 1 | 2021 | 13076 | 0.150 |
Why?
|
Cohort Studies | 5 | 2021 | 41649 | 0.150 |
Why?
|
Cellulitis | 1 | 2009 | 206 | 0.140 |
Why?
|
Phlebography | 1 | 2018 | 328 | 0.140 |
Why?
|
Genotype | 3 | 2018 | 13024 | 0.140 |
Why?
|
Ultrasonography, Doppler | 1 | 2018 | 460 | 0.130 |
Why?
|
Drug Eruptions | 1 | 2009 | 335 | 0.130 |
Why?
|
Skin Neoplasms | 2 | 2014 | 5849 | 0.130 |
Why?
|
Hemarthrosis | 1 | 2016 | 39 | 0.130 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2021 | 622 | 0.130 |
Why?
|
Patient Readmission | 1 | 2010 | 3286 | 0.130 |
Why?
|
Diagnosis, Differential | 3 | 2018 | 12976 | 0.130 |
Why?
|
Edetic Acid | 1 | 2016 | 274 | 0.120 |
Why?
|
Kidney Neoplasms | 1 | 2011 | 4274 | 0.120 |
Why?
|
Nail Diseases | 1 | 2014 | 54 | 0.110 |
Why?
|
Pilot Projects | 2 | 2018 | 8733 | 0.110 |
Why?
|
Pandemics | 2 | 2024 | 8703 | 0.110 |
Why?
|
Thrombelastography | 1 | 2016 | 193 | 0.110 |
Why?
|
Urogenital Neoplasms | 1 | 2014 | 129 | 0.110 |
Why?
|
Platelet Count | 1 | 2016 | 782 | 0.110 |
Why?
|
Cross-Sectional Studies | 3 | 2021 | 26318 | 0.100 |
Why?
|
Genes, X-Linked | 1 | 2013 | 129 | 0.100 |
Why?
|
Eye Neoplasms | 1 | 2014 | 304 | 0.100 |
Why?
|
Immunoassay | 1 | 2016 | 741 | 0.100 |
Why?
|
Inpatients | 1 | 2024 | 2564 | 0.100 |
Why?
|
Survival Rate | 2 | 2020 | 12795 | 0.100 |
Why?
|
Treatment Outcome | 7 | 2021 | 65188 | 0.090 |
Why?
|
Mucous Membrane | 1 | 2014 | 657 | 0.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 11868 | 0.090 |
Why?
|
Vascular Surgical Procedures | 1 | 2019 | 1485 | 0.090 |
Why?
|
Leukemia, Biphenotypic, Acute | 1 | 2010 | 32 | 0.090 |
Why?
|
Prevalence | 2 | 2018 | 15842 | 0.090 |
Why?
|
Structure-Activity Relationship | 1 | 2016 | 3051 | 0.090 |
Why?
|
Genes, Recessive | 1 | 2013 | 624 | 0.090 |
Why?
|
Leukemia, T-Cell | 1 | 2010 | 102 | 0.090 |
Why?
|
Binding Sites | 1 | 2019 | 6001 | 0.090 |
Why?
|
Genes, Dominant | 1 | 2013 | 856 | 0.090 |
Why?
|
Enzyme Activation | 1 | 2016 | 3586 | 0.090 |
Why?
|
Family | 1 | 2021 | 3209 | 0.080 |
Why?
|
Furans | 1 | 2011 | 198 | 0.080 |
Why?
|
Hospitals | 1 | 2022 | 3888 | 0.080 |
Why?
|
Prospective Studies | 3 | 2023 | 54802 | 0.080 |
Why?
|
Diagnostic Errors | 1 | 2016 | 1275 | 0.080 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2010 | 533 | 0.080 |
Why?
|
Vincristine | 1 | 2011 | 1039 | 0.080 |
Why?
|
Hospitals, Pediatric | 1 | 2017 | 1846 | 0.080 |
Why?
|
Protein Conformation | 1 | 2016 | 3946 | 0.070 |
Why?
|
Remission Induction | 2 | 2011 | 2411 | 0.070 |
Why?
|
Jugular Veins | 1 | 2009 | 211 | 0.070 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2011 | 2505 | 0.070 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2011 | 703 | 0.070 |
Why?
|
Exons | 1 | 2013 | 2391 | 0.070 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2014 | 961 | 0.070 |
Why?
|
Thiophenes | 1 | 2011 | 569 | 0.070 |
Why?
|
Logistic Models | 2 | 2018 | 13266 | 0.070 |
Why?
|
Incidence | 3 | 2022 | 21480 | 0.070 |
Why?
|
Pedigree | 1 | 2014 | 4526 | 0.060 |
Why?
|
Models, Molecular | 1 | 2016 | 5379 | 0.060 |
Why?
|
Calcium | 1 | 2019 | 5767 | 0.060 |
Why?
|
Case-Control Studies | 2 | 2021 | 22223 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 3 | 2019 | 36532 | 0.060 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4108 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2022 | 10383 | 0.060 |
Why?
|
Cell Separation | 1 | 2011 | 1718 | 0.060 |
Why?
|
Recurrence | 1 | 2018 | 8501 | 0.060 |
Why?
|
Cyclophosphamide | 1 | 2011 | 2228 | 0.060 |
Why?
|
Transplantation Conditioning | 1 | 2012 | 1635 | 0.060 |
Why?
|
Hodgkin Disease | 1 | 2012 | 1383 | 0.060 |
Why?
|
Doxorubicin | 1 | 2011 | 2230 | 0.060 |
Why?
|
Physicians | 1 | 2022 | 4588 | 0.050 |
Why?
|
Mutation, Missense | 1 | 2013 | 2589 | 0.050 |
Why?
|
Base Sequence | 1 | 2014 | 12403 | 0.050 |
Why?
|
Age Factors | 2 | 2021 | 18380 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 2 | 2014 | 18071 | 0.050 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2010 | 1608 | 0.050 |
Why?
|
Survival Analysis | 1 | 2014 | 10070 | 0.050 |
Why?
|
Homeodomain Proteins | 1 | 2010 | 2428 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2009 | 7478 | 0.040 |
Why?
|
Embolectomy | 1 | 2021 | 130 | 0.040 |
Why?
|
Tumor Suppressor Proteins | 1 | 2010 | 2796 | 0.040 |
Why?
|
Flow Cytometry | 1 | 2011 | 5881 | 0.040 |
Why?
|
Head and Neck Neoplasms | 1 | 2014 | 2921 | 0.040 |
Why?
|
Repressor Proteins | 1 | 2010 | 2968 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2022 | 15747 | 0.040 |
Why?
|
Prothrombin Time | 1 | 2019 | 116 | 0.040 |
Why?
|
Cognition | 1 | 2017 | 7049 | 0.040 |
Why?
|
Graft vs Host Disease | 1 | 2012 | 3078 | 0.040 |
Why?
|
North America | 1 | 2022 | 1285 | 0.040 |
Why?
|
Radiology, Interventional | 1 | 2022 | 485 | 0.040 |
Why?
|
Depression | 1 | 2017 | 8237 | 0.030 |
Why?
|
Melanoma | 1 | 2014 | 5719 | 0.030 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2010 | 3646 | 0.030 |
Why?
|
Neutropenia | 1 | 2019 | 893 | 0.030 |
Why?
|
Consensus | 1 | 2022 | 3202 | 0.020 |
Why?
|
Antineoplastic Agents | 2 | 2012 | 13648 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2019 | 4850 | 0.020 |
Why?
|
Bacteremia | 1 | 2018 | 989 | 0.020 |
Why?
|
Acute Disease | 1 | 2021 | 7232 | 0.020 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2018 | 855 | 0.020 |
Why?
|
Anemia | 1 | 2019 | 1511 | 0.020 |
Why?
|
United States | 1 | 2018 | 72903 | 0.020 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 2010 | 348 | 0.020 |
Why?
|
Combined Modality Therapy | 2 | 2012 | 8529 | 0.020 |
Why?
|
Gestational Age | 1 | 2018 | 3609 | 0.020 |
Why?
|
Hematologic Diseases | 1 | 2012 | 500 | 0.020 |
Why?
|
Catheters, Indwelling | 1 | 2009 | 438 | 0.020 |
Why?
|
Middle Aged | 1 | 2021 | 223009 | 0.020 |
Why?
|
Sequence Deletion | 1 | 2010 | 1495 | 0.020 |
Why?
|
Translocation, Genetic | 1 | 2010 | 1394 | 0.010 |
Why?
|
Length of Stay | 1 | 2018 | 6485 | 0.010 |
Why?
|
Sex Factors | 1 | 2018 | 10603 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 4562 | 0.010 |
Why?
|
Bone Marrow Transplantation | 1 | 2010 | 2729 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2012 | 6832 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2012 | 6499 | 0.010 |
Why?
|
Risk Assessment | 1 | 2022 | 24282 | 0.010 |
Why?
|
Ultrasonography | 1 | 2009 | 5993 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2010 | 12768 | 0.010 |
Why?
|